黄斑変性症（AMD）及び糖尿病性網膜症（DR）薬の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D005-00603 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール • 産業分類：医療・製薬

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、黄斑変性症（AMD）及び糖尿病性網膜症（DR）薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。黄斑変性症（AMD）及び糖尿病性網膜症（DR）薬の種類別市場規模（黄斑変性薬、糖尿病性網膜症薬）、用途別市場規模（50〜60歳、60〜70歳、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Novartis、Neurotech Pharmaceuticals、Bayer Healthcare、Roche、Allergan、Regeneron Pharmaceuticals ・地域別グローバル市場分析 2015年-2020年 ・黄斑変性症（AMD）及び糖尿病性網膜症（DR）薬の北米市場（アメリカ、カナダ、メキシコ） ・黄斑変性症（AMD）及び糖尿病性網膜症（DR）薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・黄斑変性症（AMD）及び糖尿病性網膜症（DR）薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・黄斑変性症（AMD）及び糖尿病性網膜症（DR）薬の南米市場（ブラジル、アルゼンチン） ・黄斑変性症（AMD）及び糖尿病性網膜症（DR）薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：黄斑変性薬、糖尿病性網膜症薬 ・用途別分析：50〜60歳、60〜70歳、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論

Market Overview
The global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market has been segmented into:
Macular Degeneration Drugs
Diabetic Retinopathy Drugs

By Application, Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs has been segmented into:
50-60 Years Old
60-70 Years Old
Other

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market.

The report offers in-depth assessment of the growth and other aspects of the Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share Analysis
Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs sales, revenue and market share for each player covered in this report.

The major players covered in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs are:
Novartis
Neurotech Pharmaceuticals
Bayer Healthcare
Roche
Allergan
Regeneron Pharmaceuticals

レポート目次

---

Table of Contents

1 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Overview
1.1 Product Overview and Scope of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs
1.2 Classification of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs by Type
1.2.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Type in 2019
1.2.3 Macular Degeneration Drugs
1.2.4 Diabetic Retinopathy Drugs
1.3 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market by Application
1.3.1 Overview: Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 50-60 Years Old
1.3.3 60-70 Years Old
1.3.4 Other
1.4 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market by Regions
1.4.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Status and Prospect (2015-2025)
2 Company Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Novartis SWOT Analysis
2.1.4 Novartis Product and Services
2.1.5 Novartis Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.2 Neurotech Pharmaceuticals
2.2.1 Neurotech Pharmaceuticals Details
2.2.2 Neurotech Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Neurotech Pharmaceuticals SWOT Analysis
2.2.4 Neurotech Pharmaceuticals Product and Services
2.2.5 Neurotech Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.3 Bayer Healthcare
2.3.1 Bayer Healthcare Details
2.3.2 Bayer Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Bayer Healthcare SWOT Analysis
2.3.4 Bayer Healthcare Product and Services
2.3.5 Bayer Healthcare Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Roche SWOT Analysis
2.4.4 Roche Product and Services
2.4.5 Roche Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.5 Allergan
2.5.1 Allergan Details
2.5.2 Allergan Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Allergan SWOT Analysis
2.5.4 Allergan Product and Services
2.5.5 Allergan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.6 Regeneron Pharmaceuticals
2.6.1 Regeneron Pharmaceuticals Details
2.6.2 Regeneron Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Regeneron Pharmaceuticals SWOT Analysis
2.6.4 Regeneron Pharmaceuticals Product and Services
2.6.5 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Players Market Share
3.2.2 Top 10 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Market Share by Regions
4.2 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
4.3 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
4.5 South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
5 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Countries
5.1 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Countries (2015-2020)
5.2 USA Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
5.3 Canada Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
5.4 Mexico Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
6 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Countries
6.1 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Countries (2015-2020)
6.2 Germany Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
6.3 UK Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
6.4 France Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
6.5 Russia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
6.6 Italy Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Countries
7.1 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Countries (2015-2020)
7.2 China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
7.3 Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
7.4 Korea Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
7.5 India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
8 South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Countries
8.1 South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Countries (2015-2020)
8.2 Brazil Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
8.3 Argentina Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs by Countries
9.1 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Countries (2015-2020)
9.2 Saudi Arabia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
9.3 UAE Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
9.4 Egypt Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
9.5 South Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Market Share by Type (2015-2020)
10.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Forecast by Type (2019-2024)
10.3 Macular Degeneration Drugs Revenue Growth Rate (2015-2025)
10.4 Diabetic Retinopathy Drugs Revenue Growth Rate (2015-2025)
11 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Segment by Application
11.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Application (2015-2020)
11.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Forecast by Application (2019-2024)
11.3 50-60 Years Old Revenue Growth (2015-2020)
11.4 60-70 Years Old Revenue Growth (2015-2020)
11.5 Other Revenue Growth (2015-2020)
12 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Forecast (2021-2025)
12.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Forecast (2021-2025)
12.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Forecast by Regions (2021-2025)
12.3 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Forecast (2021-2025)
12.4 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Forecast (2021-2025)
12.6 South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Novartis Corporate Information, Location and Competitors
Table 6. Novartis Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Major Business
Table 7. Novartis Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Total Revenue (USD Million) (2017-2018)
Table 8. Novartis SWOT Analysis
Table 9. Novartis Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Solutions
Table 10. Novartis Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Neurotech Pharmaceuticals Corporate Information, Location and Competitors
Table 12. Neurotech Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Major Business
Table 13. Neurotech Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Total Revenue (USD Million) (2018-2019)
Table 14. Neurotech Pharmaceuticals SWOT Analysis
Table 15. Neurotech Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Solutions
Table 16. Neurotech Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Bayer Healthcare Corporate Information, Location and Competitors
Table 18. Bayer Healthcare Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Major Business
Table 19. Bayer Healthcare Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Total Revenue (USD Million) (2017-2018)
Table 20. Bayer Healthcare SWOT Analysis
Table 21. Bayer Healthcare Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Solutions
Table 22. Bayer Healthcare Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Roche Corporate Information, Location and Competitors
Table 24. Roche Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Major Business
Table 25. Roche Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Total Revenue (USD Million) (2017-2018)
Table 26. Roche SWOT Analysis
Table 27. Roche Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Solutions
Table 28. Roche Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Allergan Corporate Information, Location and Competitors
Table 30. Allergan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Major Business
Table 31. Allergan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Total Revenue (USD Million) (2017-2018)
Table 32. Allergan SWOT Analysis
Table 33. Allergan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Solutions
Table 34. Allergan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Regeneron Pharmaceuticals Corporate Information, Location and Competitors
Table 36. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Major Business
Table 37. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Total Revenue (USD Million) (2017-2018)
Table 38. Regeneron Pharmaceuticals SWOT Analysis
Table 39. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Solutions
Table 40. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) by Players (2015-2020)
Table 42. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Share by Players (2015-2020)
Table 43. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) by Regions (2015-2020)
Table 44. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Regions (2015-2020)
Table 45. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Countries (2015-2020)
Table 46. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries (2015-2020)
Table 47. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 48. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 49. South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Countries (2015-2020)
Table 50. South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries (2015-2020)
Table 51. Middle East and Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 52. Middle East and Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries (2015-2020)
Table 53. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) by Type (2015-2020)
Table 54. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Share by Type (2015-2020)
Table 55. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Forecast by Type (2021-2025)
Table 56. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Application (2015-2020)
Table 57. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Share by Application (2015-2020)
Table 58. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Forecast by Application (2021-2025)
Table 59. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Picture
Figure 2. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Type in 2019
Figure 3. Macular Degeneration Drugs Picture
Figure 4. Diabetic Retinopathy Drugs Picture
Figure 5. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Application in 2019
Figure 6. 50-60 Years Old Picture
Figure 7. 60-70 Years Old Picture
Figure 8. Other Picture
Figure 9. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Share by Players in 2019
Figure 17. Global Top 5 Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share in 2019
Figure 18. Global Top 10 Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Regions (2015-2020)
Figure 22. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Regions in 2018
Figure 23. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 24. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 26. South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 28. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries (2015-2020)
Figure 29. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries in 2019
Figure 30. USA Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 31. Canada Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 32. Mexico Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 33. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries (2015-2020)
Figure 34. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries in 2019
Figure 35. Germany Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 36. UK Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 37. France Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 38. Russia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 39. Italy Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries in 2019
Figure 42. China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 43. Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 44. Korea Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 45. India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 47. South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries (2015-2020)
Figure 48. South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries in 2019
Figure 49. Brazil Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 50. Argentina Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 54. UAE Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 55. Egypt Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 56. South Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue and Growth Rate (2015-2020)
Figure 57. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Share by Type (2015-2020)
Figure 58. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Share by Type in 2019
Figure 59. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share Forecast by Type (2021-2025)
Figure 60. Global Macular Degeneration Drugs Revenue Growth Rate (2015-2020)
Figure 61. Global Diabetic Retinopathy Drugs Revenue Growth Rate (2015-2020)
Figure 62. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Share by Application (2015-2020)
Figure 63. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Share by Application in 2019
Figure 64. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share Forecast by Application (2021-2025)
Figure 65. Global 50-60 Years Old Revenue Growth Rate (2015-2020)
Figure 66. Global 60-70 Years Old Revenue Growth Rate (2015-2020)
Figure 67. Global Other Revenue Growth Rate (2015-2020)
Figure 68. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Forecast (2021-2025)
Figure 72. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Forecast (2021-2025)
Figure 74. South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel

---